Cancers autres (hors CCR et CHC)

Présent dans le moteur de recherche:

Oui

Early metabolic response to chemoradiotherapy by interim FDG PET/CT is associated with better overall survival and histological response in esophageal cancers

Soumis par Sylvain MANFREDI le mer, 17/07/2019 - 00:00

Prediabetes and diabetes in relation to risk of gastric adenocarcinoma

Soumis par Sylvain MANFREDI le mer, 17/07/2019 - 00:00

Association of time to colonoscopy after a positive fecal test result and fecal hemoglobin concentration with risk of advanced colorectal neoplasia

Soumis par Sylvain MANFREDI le mer, 19/06/2019 - 00:00

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study

Soumis par Sylvain MANFREDI le mer, 19/06/2019 - 00:00

Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer

Soumis par Sylvain MANFREDI le mer, 19/06/2019 - 00:00

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra

Soumis par Yann TOUCHEFEU le mer, 19/06/2019 - 00:00

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Soumis par Yann TOUCHEFEU le mer, 22/05/2019 - 00:00

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.

Soumis par Yann TOUCHEFEU le mer, 22/05/2019 - 00:00

Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.

Soumis par Yann TOUCHEFEU le lun, 20/05/2019 - 00:00

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Soumis par Sylvain MANFREDI le lun, 20/05/2019 - 00:00

Pages